申请人:Asahi Kasei Pharma Corporation
公开号:US20200347046A1
公开(公告)日:2020-11-05
A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP
4
receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.
以下通用公式(1)所代表的新化合物,或其盐,具有优越的EP4受体激动剂活性,以及含有该化合物或其盐作为活性成分的药物,可用于促进骨生成、治疗和/或促进骨折愈合等用途。